MA-VERISTAT
29.5.2024 14:43:32 CEST | Business Wire | Press release
Veristat, the Science-First Full Service CRO and Consultancy, is pleased to announce that Gabriela Rosu, M.D., has joined as Senior Director, Global Medical Affairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529939891/en/
Gabriela Rosu, MD Senior Director, Global Medical Affairs Veristat (Photo: Business Wire)
Dr. Rosu is a seasoned professional with over twenty years of experience in scientific and clinical fields, having significantly contributed to the planning and execution of pivotal activities that have led to the approval and commercialization of groundbreaking therapies.
Her appointment is timely, coming just before the American Society of Clinical Oncology’s (ASCO, #ASCO24) Annual Meeting, an event where Dr. Rosu has historically made impactful contributions through numerous abstracts.
Patrick Flanagan, CEO of Veristat, praised Dr. Rosu's dedication, "Dr. Rosu’s fervent commitment to collaboration enhances our ability to make informed decisions, crucially improving patient experiences in clinical trials and ensuring favorable outcomes. Her profound insight into the nuances of oncology therapy development is invaluable, particularly as we continue to focus on optimizing treatment strategies in this area."
Veristat’s Medical Affairs team is at the forefront of evaluating scientific data to address the increasing complexity of biotherapeutic compounds and diverse patient demographics in clinical trials. The team is instrumental in fostering communication and generating essential evidence to support patient safety and optimize treatment outcomes, especially for those with rare and complex diseases (#oncology, #cancer, #raredisease).
In her new role, Dr. Rosu will oversee the global expansion of the medical and safety/pharmacovigilance teams. Her extensive background includes senior medical affairs positions at leading global CROs, where she oversaw medical monitoring for various oncology trials, advised on protocol development, risk mitigation strategies, and strategic development with a focus on patient safety and patient outcomes. Dr. Rosu's experience is particularly notable in immuno-oncology, focusing on managing compound toxicity.
Before transitioning to the CRO industry, Dr. Rosu held significant roles such as Chief Medical Officer at IMV Inc. and Global Medical Advisor at Novo Nordisk Healthcare, where she led clinical developments in oncology and coagulation disorders, among other responsibilities.
Dr. Rosu earned her Doctor of Medicine degree in Romania and has maintained active participation in prestigious organizations such as the American Society for Clinical Oncology (ASCO, #ASCO) and the European Society for Medical Oncology (ESMO, #ESMO).
Reflecting on her new position, Dr. Rosu stated, "I am honored to lead as Senior Director, Global Medical Affairs at Veristat, aligning with the company’s strategic vision to pioneer the development and commercialization of innovative treatments for rare diseases. My dedication to enhancing patient experiences in clinical trials and fostering the development of safe and effective therapies remains unwavering. I look forward to contributing to Veristat’s dynamic team and its noble mission."
About Veristat
Veristat is the Science-First CRO™ and Consultancy that integrates full service clinical trial execution, regulatory affairs and safety, and strategic advisor services to rapidly advance the development, approval, and commercialization of novel therapies (#NovelTherapies) around the globe. With 30 years of experience solving sponsors' unique and complex clinical, statistical, and regulatory challenges, #Veristat Science-First experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders.
Veristat's focus on novel drug development has led to success when handling any unknown that arises, from the simplest to most complex, across numerous therapeutic areas including rare/ultra-rare disease, advanced therapies, oncology, and biologics including cell and gene therapies (#cellandgenetherapy), enabling sponsors to succeed in extending and saving patients’ lives. Sponsors collaborate with Veristat Science-First experts who care— like they do. It is not just business for Veristat, it’s personal.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529939891/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Healthcare Accelerates AI Investment as Governance and Risk Shape the Path to Value19.11.2026 10:26:00 CET | Press release
HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory complexity, validation requirements, and organizational readiness HTEC, the global AI technology and engineering leader, today released new research examining how healthcare and life sciences organizations measure, track, and realize value from AI investments, as well as the risks and barriers preventing them from doing so at scale. The findings reveal that while investment continues to rise, organizations that successfully scale AI focus not only on technology, but also on the governance, workforce adoption, and operational foundations needed to track, prove, and realize impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119322683/en/ HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory c
Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 10:00:00 CET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit
Twilio Powers Chelsea FC to Cut Campaign Launch Times from 48 Hours to Under 15 Minutes19.11.2026 10:00:00 CET | Press release
Twilio Segment gives Chelsea a more connected view of its global fanbase for real-time responses to personal interests and match moments on the pitch Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its SIGNAL World Tour London, by unveiling that Chelsea Football Club has slashed campaign launch times from 48 hours to under 15 minutes with Twilio Segment. Building a Single View of the Global Fan Chelsea’s global fans interact with the Club across matchdays, ticketing, its mobile app, ecommerce and other digital experiences. Historically, these interactions sat across siloed systems, creating duplicate customer records for a single fan. By consolidating its data, Chelsea removed over 460,000 duplicate records. With this cleaner and unified fan database, campaign launch time has been reduced from 48+ hours to under 15 minutes. Beyond the Pitch: Elevating the Fan Experience Chelsea is now able to send its fans highly relevant messages tailored to t
EDAN Presents Integrated Medical Innovations at MEDICA 2026, Strengthening Global Healthcare Connections19.11.2026 09:49:00 CET | Press release
Edan Instruments, Inc. (300206. SZ), a global provider of medical devices and healthcare solutions, is presenting its latest innovations at MEDICA 2026, taking place November 16–19 in Düsseldorf. The event provides an important platform for industry exchange and an opportunity for EDAN to engage with European partners on evolving healthcare needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118813326/en/ “Germany and Europe are important partners in the global healthcare industry. As China’s medical technology sector expands internationally, closer collaboration with European healthcare professionals and industry partners can create opportunities for shared progress,” said Alex You, Senior Director of Marketing, Customer Service, Global Connectivity & Integration at EDAN. “By understanding local clinical needs and translating them into accessible, reliable solutions, we can contribute to more effective healthcare. MEDI
Ant International's Alipay+ to Connect over 50 Global E-Wallets with Pix of Brazil19.11.2026 09:43:00 CET | Press release
Expanding Alipay+'s national QR scheme connections to 16, spanning Asia, the Middle East and Latin AmericaEnabling international travellers to pay with home wallets at Pix merchants across Brazil, supporting local businesses and inbound tourism Ant International today announced that Alipay+, its global wallet gateway that links over 50 global digital wallets and banking apps, is connected to Pix, Brazil's national instant payment system, expanding cross-border digital payment access for international travellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119229229/en/ Ant International's global wallet gateway Alipay+ is connecting over 50 e-wallets and banking apps to Pix Powered by Ant International’s AI-native payment and risk management capabilities, the service allows international travellers using their familiar payment apps to scan Pix QR codes at shops, restaurants, and attractions nationwide, without downloadi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
